How can researchers unlock the potential of plant-based extracellular vesicles (EVs) in cancer therapy?

How can researchers unlock the potential of plant-based extracellular vesicles (EVs) in cancer therapy?
A recent review published in Materials Advances highlights the transformative potential of plant-derived EVs in cancer therapy. These nanoscale vesicles, naturally produced by plants, offer a sustainable and effective approach to delivering anti-cancer drugs while minimizing side effects.

Key Insights from the Research:
•⁠ ⁠Bioactive Molecules: Plant EVs are naturally enriched with therapeutic compounds, such as:
1.⁠ ⁠Flavonoids and terpenoids are known for their antioxidant and anti-inflammatory properties.
2.⁠ ⁠miRNAs, which can regulate tumor-suppressing genes.

•⁠ ⁠Biocompatibility: Plant EVs exhibit low immunogenicity, making them safer than synthetic nanoparticles for therapeutic applications.
•⁠ ⁠Potential for Drug Delivery: Engineered EVs can encapsulate anti-cancer agents, ensuring targeted and controlled release, which improves therapeutic efficacy while reducing off-target effects.
•⁠ ⁠Sustainability: Derived from renewable plant sources, EVs provide a scalable and eco-friendly alternative for drug delivery.
Challenges to Overcome:
•⁠ ⁠Targeting Specificity: Unmodified EVs may lack precision for delivering drugs to cancer cells.
•⁠ ⁠Drug Loading Efficiency: Efficiently encapsulating drugs into EVs without compromising their structure is crucial.
•⁠ ⁠Reproducibility: Consistent methods for isolating and preparing EVs are essential for clinical applications.

Read the full paper here: https://pubs.rsc.org/en/content/articlelanding/2025/ma/d4ma01189